Article Text

Download PDFPDF

#533 Treatment results of stage IIIC2 locally advanced cervical cancer patients treated with radiochemotherapy
  1. Senem Alanyali1,
  2. Fethiye Odaci1,
  3. Nuri Yildirim2 and
  4. Zeynep Özsaran1
  1. 1Ege University, Department of Radiation Oncology, Izmir, Türkiye
  2. 2Ege University, Gynecologic Oncology, Izmir, Türkiye


Introduction/Background The aim is to analyze treatment results and prognostic factors of stage IIIC2 cervical cancer patients treated with radiochemotherapy.

Methodology 21 out of 239 Stage IIIC2 cervical cancer patients treated between 2012–2021 were included.Patients with paraaortic lymph nodes(PALN) prophylactically irradiated,with PALN recurrences,with PALN metastases found at PALN dissection and patients with distant metastases were excluded.A total of 21 locally advanced cervical cancer patients with PALN metastases initially diagnosed with PET-CT were evaluated.Radiotherapy was 3D conformal/IMRT-VMAT,concurrent chemotherapy was weekly 40mg/m2 cisplatin or 2AUC carboplatin.Primary tumor, pelvic LNs and parametrium were treated with 50.4Gy(1.8Gy per fraction)then parametrium and metastatic pelvic/PA LNs were boosted up to 54–60Gy.Extended RT field was up to level of T12/L1. Brachytherapy(4x7Gy or 5x5Gy) was applied to 18 patients.

Results Median age was 54(range:29–89).Sixteen(76.2%) patients had SCC.Median tumor size was 4.9cm(range:2.4–10cm).Thirteen patients(61.9%) had vaginal,19 (90.5%) had parametrial infiltration.Three patients had hydronephrosis.Four(19%) patients had single,17(81%) had multiple PALN metastases.Median diameter of PALN is 1.5cm(1–3.9 cm).

Twelve 12(57%) patients had complete response, and 9 patients(43%) had either partial response/progressive disease.Eight patents received chemotherapy due to the residual/progressive disease.Among 12 patients with complete response to RCT;5 patients died.One is due to local recurrence,2 due to the distant metastases,1 due to the primary lung cancer with brain metastases and 1 due to the complication.

OS was 24 months(8–112 months).Two-year DFS was 52% and OS was 47%. Presence of hydronephrosis(p:0.004), poor response/progressive disease at 3 months(p:0.000),radiotherapy without brachytherapy(p:0.002) were found unfavorable prognostic factors for DFS.Size of the PALN metastases(p:0,006),poor response/progressive disease at 3 months(p: 0.002) and radiotherapy without brachytherapy(p:0,006) were found unfavorable prognostic factors for OS.

Conclusion Even in the modern staging and treatment era,outcome of treatment in stage IIIC2 cervical cancer patients is still disappointing.Systemic treatment approaches with cytotoxic drugs, immunotherapy and/or targeted therapy agents should be integrated to new treatment protocols.

Disclosures None

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.